Articles tagged with Amyotrophic Lateral Sclerosis
Researchers at Mayo Clinic discovered an abnormal protein C9RANT that accumulates in the brains of patients with ALS and frontotemporal dementia. The findings provide a potentially new therapeutic target and biomarker to confirm diagnosis of these diseases.
Researchers created motor neurons and astrocytes from a patient's skin cells, revealing that abnormal TDP-43 protein causes astrocyte death. This finding provides fresh insight into the mechanisms of motor neurone disease, a devastating condition with no cure or effective treatment.
Researchers have identified a new genetic mutation in the ARHGEF28 gene that is present in all cases of amyotrophic lateral sclerosis (ALS). The protein arising from this gene appears to play a critical role in the disease, and understanding its function could lead to targeted therapies.
Researchers found that stem cell transplantation significantly extended the lifespan of mice with ALS by 20 days and improved their neuromuscular function by 15 percent. This breakthrough study suggests that stem cells may represent a promising avenue for effective cell-based treatment for ALS and other neurodegenerative diseases.
In a groundbreaking study, researchers found that transplanted neural stem cells slow ALS disease onset and progression by producing protective molecules and reducing inflammation. The treatment improves motor function and prolongs survival in ALS mice, offering new hope for treating this devastating disease.
Researchers have shown that transplanted neural stem cells slow ALS onset and progression, improving motor function and survival time. The study also found that these cells promote the production of protective molecules and reduce inflammation.
A new study by LSUHSC researchers has found that the ability of a protein called FUS to bind to RNA is essential to the development of Amyotrophic Lateral Sclerosis (ALS). By mutating FUS and blocking its RNA binding, the team was able to suppress ALS-related neurodegeneration in fruit fly models.
Researchers used baker's yeast to identify a chink in the armor of Lou Gehrig's disease, discovering that blocking Dbr1 function can stop protein clumping and allow cells to live normally. The findings suggest therapeutic approaches aimed at blocking Dbr1 should be explored.
A team of scientists at Scripps Research Institute has been awarded $2.1 million to study compounds that may improve the quality of life for ALS patients by inhibiting the JNK enzyme. The study aims to develop a neuroprotective drug to prevent motor neuron death and lengthen patients' lifespan.
Jenny Ross, a UMass Amherst biophysicist, has won the 2013 Margaret Oakley Dayhoff Award for her substantial contributions to biophysical research. The award recognizes her study of microtubules, which provide structure to cells and are crucial in various cellular processes.
A new class of small molecules, P7C3 series, has been identified to block cell death in animal models of Parkinson's disease and amyotrophic lateral sclerosis. The compounds protect newborn neurons from cell death and correlate with improvement of disease symptoms.
Researchers have discovered a molecule that could lead to a future ALS treatment, modifying the course of the disease in zebrafish models. The EphA4 receptor was found to play a key role in the mechanism of ALS, with its expression linked to disease severity and recovery.
Researchers at UMass Chan Medical School have discovered a gene that influences survival time in amyotrophic lateral sclerosis (ALS). The study found that blocking the activity of EphA4 receptor substantially extends the lifespan of people with the disease. Additionally, a new ALS gene (profilin-1) identified last month works in conjun...
Researchers at Brigham and Women's Hospital have identified a blood biomarker for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The discovery may lead to the development of new treatments for the debilitating neurological disease, which affects approximately 30,000 Americans.
Research by IDIBELL-UB reveals that exposure to IDPN nitrile leads to accumulations of neurofilaments similar to those found in amyotrophic lateral sclerosis. This finding suggests a potential link between environmental toxins and ALS, with implications for new treatment approaches.
Researchers identified gene mutations in profilin that affect nerve cell structure and growth, shedding light on how ALS destroys cells. The study provides a new piece of the puzzle in understanding ALS mechanisms, supporting existing studies on cell cytoskeleton disruptions.
Researchers at Ruhr-University Bochum successfully transformed spinal cord stem cells into immature nerve cells using sodium chlorate. This development holds promise for improving cell replacement therapies in diseases such as Parkinson's, multiple sclerosis, and amyotrophic lateral sclerosis.
Researchers discovered a mutation in the p150glued protein linked to hereditary motor neuropathy 7B (HMN7B) and amyotrophic lateral sclerosis (ALS), disrupting cargo transport in neurons. The study found that when this protein is compromised, control of cargo transport is lost, leading to disease.
A new study reveals the immune system and inflammation may play a significant role in Lou Gehrig's disease, specifically targeting motor neurons for clean-up by macrophages. Resolvin D1, an omega-3 fatty acid derivative, was found to curb inflammation and block harmful proteins, offering a potential new approach to treating ALS.
Researchers have identified a genetic mutation in the DYNC1H1 gene as the cause of rare form of spinal muscular atrophy with lower extremity predominance. This disease affects nerve cells controlling muscles of the legs and has a good prognosis, although patients are moderately disabled.
Researchers found that ALS patients who receive feeding tubes before emergency situations fare better, with longer median survival and lower mortality rates. Patients also have polarized preferences for expensive treatments like Riluzole, which modestly prolongs length of life.
A recent study has created motor neurons using skin cells from a patient with inherited MND, discovering abnormalities in protein TDP-43 that lead to motor neuron cell death. This breakthrough model could speed up the discovery of new treatments for the devastating disease.
A study published in PNAS refutes the long-held hypothesis that organelle transport deficits cause axon degeneration in ALS. Instead, reduction and initiation appear to occur through different mechanisms, making axonal organelle transport an unsuitable therapeutic target.
A study published in Cell reveals that only a handful of genes and proteins guide the growth of motor neurons, which eventually connect with muscles. This discovery may lead to new therapies for ALS and provide insight into certain cancers.
A study found that blocking a protein called AMPK helps increase animal mobility and reduce nerve cell death in animal models of amyotrophic lateral sclerosis (ALS). The findings suggest energy deficits may contribute to neurodegenerative disorders like ALS, offering new directions for treatment.
Researchers at Northwestern University have discovered a second faulty gene, sequestosome1, contributing to the degeneration of motor neurons in ALS. The study provides new insights into the disease's progression and potential targets for drug therapies.
A phase 2 trial of the novel drug dexpramipexole showed it can slow symptom progression and reduce mortality in ALS patients. The study found a significant dose-dependent effect, with slower disease progression and reduced risk of death at higher dosages.
Researchers found that TDP-43 binds to NF-kB p65 in spinal cords of ALS patients, promoting inflammation and killing neurons. Treatment with an agent blocking p65 activity eased disease symptoms in a mouse model.
A newly identified type of astrocyte cell displays atypical behavior and causes motor neuron death, suggesting a new target for ALS therapies. The discovery offers hope for slowing or stopping the progression of this devastating disease, affecting 30,000 Americans.
The FDA has approved a diaphragm pacing system to help ALS patients breathe longer without the aid of a ventilator. The system, called NeuRx Diaphragm Pacing System, provides electrical stimulation to the diaphragm muscles and conditions them to delay respiratory failure.
A gene for Lou Gehrig's disease and frontotemporal dementia has been identified by researchers at the University of California - San Francisco. The mutated gene, C9ORF72, is associated with nearly 12% of familial cases and over 22% of sporadic cases of the diseases., Scientists have discovered a genetic mutation that triggers both Lou ...
A recent study by Mayo Clinic researchers has found a genetic abnormality that is the most common cause of two neurodegenerative diseases: frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The mutation, located in the C9ORF72 gene, was found in nearly 12% of familial FTD patients and over 22% of familial ALS patients.
Scientists have identified a mutation in the SIGMAR1 gene associated with juvenile amyotrophic lateral sclerosis (ALS), affecting Sigma-1 receptors involved in motor neuron function and disease development. The study suggests that further exploration of this receptor may uncover potential therapeutic targets for ALS.
Researchers have created a new model of ALS using human cells from autopsied tissue, finding that astrocytes secrete toxic factors that cause nerve cell degeneration. The study suggests that inflammatory responses and SOD1 function contribute to both sporadic and familial ALS.
A team of scientists used induced pluripotent stem cells from patients with inherited ALS to reveal how reduced VAPB protein levels contribute to the disease. The study provides a novel in vitro model of ALS and offers an unprecedented opportunity to answer questions about the disease's pathogenesis.
A study by Dr. Udai Pandey's lab at LSU Health Sciences Center found that blocking the abnormal movement of a mutated FUS protein in fruit flies can block the ALS disease process. The research provides a valuable resource for performing drug screens to identify potential therapeutic interventions.
Nine patients with amyotrophic lateral sclerosis (ALS) were treated with Neuralstem's spinal cord stem cells, showing no unresolved serious adverse reactions or death. The trial indicates the feasibility of transplanting stem cells directly into the spinal cord, paving the way for future treatments.
The phase I safety trial of Neuralstem's human spinal cord stem cells in amyotrophic lateral sclerosis (ALS) will be presented at the American Academy of Neurology Annual Meeting, featuring interim safety data on nine patients. The trial is designed to evaluate the safety of the cells and surgery procedure for ALS treatment.
The study found that over one-third of genes affected by TDP-43 are involved in the central nervous system. The protein also affects alternative splicing of many genes, including its own RNA message. This loss of regulation leads to more TDP-43 accumulation and neuron damage.
Scientists have discovered a new way to generate human motor nerve cells, helping research into motor neurone disease. This breakthrough enables the creation of different types of motor neurons, allowing researchers to study their vulnerability to disease.
A study analyzing data from over 1.1 million participants found that cigarette smoking is associated with an increased risk of developing amyotrophic lateral sclerosis (ALS). Smokers had a 42% higher risk of developing ALS compared to non-smokers, while former smokers had a 44% increased risk.
Researchers discovered a defect in hair follicle stem cells conversion to progenitor cells in AGA. Aspirin-derived resolvins reduced pro-inflammatory molecules and cells in a mouse model of inflammation. A new approach to vaccine design against systemic fungal infections requires inducing Th17 cells.
Researchers at Brandeis University developed a chemical rope to stabilize the SOD1 protein, which causes familial ALS. The approach potentially solves the instability problem, even at high temperatures.
Experts in motor neuron diseases challenge a recent study's claim that repetitive head trauma causes ALS, citing lack of clinical and pathological evidence. The editorial aims to dispel doubts on Lou Gehrig's ALS diagnosis.
A study funded by the Motor Neurone Disease Association has identified a common signature of nerve damage in MND patients' brains, using advanced MRI techniques. This finding holds promise for a biomarker that could improve diagnosis speed and accuracy, as well as assess future treatments.
A disease mechanism linking hereditary amyotrophic lateral sclerosis (ALS) to the more common sporadic form has been discovered. The findings point to the P38 enzyme as a key factor in disrupting axonal transport, a disruption that results in loss of connectivity and symptoms of ALS long before the neurons actually die.
A team of researchers identified a way to preserve nerve cells in motor neuron disease by preventing symptom onset, weight loss, and paralysis. This discovery provides a new avenue for the development of therapeutics for ALS and other motor neuron diseases.
Researchers identified ways to preserve motor neuron cells in ALS and enhance CD8+ T cell therapy for leukemia. Expanding immune suppressors via TNFRSF25 could prevent allergic lung inflammation in asthma. These findings may pave the way for new therapeutic approaches for these diseases.
A new study published in Neurology found that lithium is not effective in treating amyotrophic lateral sclerosis (ALS) due to a high dropout rate and serious side effects. The research involved 171 people with ALS, but showed no difference between those receiving therapeutic or subtherapeutic doses of lithium.
New research reveals the TRPML1 channel plays a crucial role in lysosome function, offering new avenues for treating conditions like ALS and CMT. The findings suggest that activating this channel could help overcome membrane traffic defects caused by disease-causing mutations.
Researchers at LA BioMed developed a novel approach to efficiently identify disease-relevant genes in human complex neurological disorders. This method was successfully applied to Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease, revealing new insights into the disease and potential diagnostic tests.
A new animal study published in Current Topics in Nutraceutical Research suggests that eating pecans daily may help protect the nervous system and delay motor neuron degeneration. The study found that vitamin E in pecans provides significant antioxidant benefits, which can fight diseases like Alzheimer's and Parkinson's.
A genetic link has been discovered between sporadic and familial forms of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. The study found that protein FUS forms characteristic inclusions in spinal motor neurons in most ALS cases, suggesting a common pathogenic pathway for motor neuron degeneration.
Researchers are developing a new test to identify the neurological origins of swallowing disorders, which affect millions of people worldwide. The test may lead to breakthrough treatments for neurodegenerative diseases like Lou Gehrig's disease and ALS.
Researchers have discovered a genetic mutation associated with motor neurone disease that causes proteins to clump together in motor neurones, leading to their death. The new finding provides strong evidence for protein aggregation as the underlying cause of MND.
A defective protein in spinocerebellar ataxia type 5 (SCA5) damages nerve cells by cutting the number of synaptic terminals and disrupting intracellular transportation. The study suggests that the complex containing beta-III-spectrin, dynactin, and dynein might also snag microtubules to prevent degeneration.
A double-blind randomized trial found no benefit of lithium in slowing ALS progression, contrary to initial promising results from a small pilot study. The trial involved 84 patients with ALS and showed that lithium plus riluzole did not slow disease progression more than riluzole alone.
A new ALS drug, talampanel, has shown some ability to slow the loss of major daily life activities such as speaking, walking and dressing. The study found that talampanel slowed progression of ALS by 30 percent, according to the ALS Functional Rating Scale.
Researchers have discovered that high levels of lead can slow the progression of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. This finding suggests that lead may activate a novel pathway able to reduce neuroinflammation and slow neurodegeneration in ALS patients.
A new study published in Neurology suggests that smoking is an established risk factor for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. The findings support the link between environmental factors and ALS occurrence, highlighting potential avenues for treatment.